Educational project on Minimal Residual Disease (MRD)  in multiple myeloma – 2026/2027

 

Background

Minimal Residual Disease (MRD) is emerging as a powerful prognostic marker in multiple myeloma, providing highly sensitive insights into residual disease beyond conventional measures. Its assessment is increasingly recognised for its potential to guide therapy, inform treatment decisions, and accelerate the evaluation of new therapeutic approaches.

Understanding MRD is essential to optimise patient management: defining its role in multiple myeloma treatment, exploring the various detection methods—including next-generation sequencing (NGS), flow cytometry, and polymerase chain reaction (PCR)—and interpreting the clinical implications for prognosis and patient outcomes.

Ongoing research is investigating emerging technologies and strategies for MRD assessment, including non-invasive approaches and their integration with targeted therapies. Advancing knowledge of MRD can support personalised treatment, improve patient outcomes, and facilitate the development of more effective therapeutic strategies.

Format

Recognising the importance of optimising multiple myeloma management through MRD assessment, Sharing Progress in Cancer Care is implementing a focused multistep project:

• Two webinars (2026)
  • MRD in multiple myeloma: foundations and clinical relevance –11 February 2026 at 18.00 CET
    Accessible free of charge – with mandatory registration – by clicking here.
  • MRD in multiple myeloma: future directions and controversies – 9 March 2026 at 18.00 CET
    Accessible free of charge – with mandatory registration – by clicking here.
• A closed virtual task force (2026)
• A manuscript summarising the most important outcomes of the task force (to be submitted by Q1 2027)

Advisory & Leadership Team

Carl Ola Landgren, University of Miami, US
Bruno Paiva, Universidad de Navarra, Pamplona, ES
Jesùs San-Miguel, Universidad de Navarra, Pamplona, ES

Acknowledgements 

This activity is supported by an unrestricted medical contribution from Sanofi. Procedures for further independent support are ongoing.

Next Steps

Additional information and updates on the progress of the activity, including the closed virtual task force and the subsequent manuscript development,  will be shared on this page in due course.